About Clene Inc.
https://clene.comClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CEO
Robert Etherington
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 18, 2018
Method of going public SPAC
Full time employees 75
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $2.24 M
52w High $0.01
52w Low $0.00
P/E 0
Volume 92.40K
Outstanding Shares 1.20B
About Clene Inc.
https://clene.comClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $15K ▼ | $5.66M ▼ | $-8.78M ▼ | -58.51K% ▼ | $-0.85 ▼ | $-7.76M ▼ |
| Q2-2025 | $27K ▼ | $5.89M ▲ | $-7.42M ▼ | -27.48K% ▼ | $-0.78 ▼ | $-6.37M ▼ |
| Q1-2025 | $81K ▼ | $4.14M ▼ | $-751K ▲ | -927.16% ▲ | $-0.09 ▲ | $261K ▲ |
| Q4-2024 | $91K ▲ | $8.73M ▲ | $-13.55M ▼ | -14.89K% ▼ | $-1.95 ▼ | $-12.63M ▼ |
| Q3-2024 | $87K | $7.88M | $-7.99M | -9.18K% | $-1.22 | $-6.56M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.92M ▲ | $22.31M ▲ | $34.67M ▲ | $-12.36M ▼ |
| Q2-2025 | $7.29M ▼ | $22.13M ▼ | $30.68M ▲ | $-8.55M ▼ |
| Q1-2025 | $9.83M ▼ | $25.31M ▼ | $30.29M ▼ | $-4.97M ▲ |
| Q4-2024 | $12.15M ▼ | $27.34M ▼ | $36.19M ▲ | $-8.86M ▼ |
| Q3-2024 | $14.64M | $31.57M | $35.69M | $-4.13M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.78M ▼ | $-3.98M ▲ | $-10.97K ▼ | $4.63M ▲ | $640K ▲ | $-3.99M ▲ |
| Q2-2025 | $-7.42M ▼ | $-4.74M ▲ | $0 | $2.13M ▼ | $-2.55M ▼ | $-4.74M ▲ |
| Q1-2025 | $-751K ▲ | $-5.01M ▼ | $0 ▲ | $2.67M ▲ | $-2.32M ▲ | $-5.01M ▼ |
| Q4-2024 | $-13.55M ▼ | $-4.87M ▼ | $-2K ▼ | $2.53M ▲ | $-2.49M ▲ | $-4.87M ▼ |
| Q3-2024 | $-7.99M | $-3.02M | $-1K | $-4.07M | $-7.04M | $-3.02M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Robert Etherington
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 18, 2018
Method of going public SPAC
Full time employees 75
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0